Physician profile
Salman Bhat
NPI 1447743448
$1,118.18
in general payments reported to CMS, 2019-2025
19 companies · $600 in 2025
The $600 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $165 · 2024: $353 · 2025: $600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,118.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $216.48 | 2024-2025 | Omnipod |
| Amgen INC. | $208.86 | 2023-2025 | Tepezza, Evenity, Repatha |
| Tandem Diabetes Care, INC. | $149.92 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Beta Bionics, INC. | $77.70 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Dexcom, INC. | $60.68 | 2024-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $58.29 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Amneal Pharmaceuticals LLC | $52.33 | 2024-2025 | Unithroid |
| Soleno Therapeutics, INC. | $42.69 | 2025 | Vykat Xr |
| Bayer Healthcare Pharmaceuticals INC. | $40.56 | 2024-2025 | |
| Medtronic, INC. | $24.75 | 2024 | Minimed 780g |
| Lilly USA, LLC | $23.84 | 2024 | Mounjaro |
| Kyowa Kirin, INC. | $23.46 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.26 | 2024 | Jardiance |
| Horizon Therapeutics Plc | $22.95 | 2023 | Tepezza |
| Recordati_rare_diseases_inc. | $20.74 | 2023 | Isturisa, Signifor Lar |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $18.36 | 2025 | Strensiq |
| Abbvie INC. | $18.31 | 2025 | |
| Cequr Corporation | $18.24 | 2024 | Cequr Simplicity |
| Rhythm Pharmaceuticals, INC. | $16.76 | 2024 | Imcivree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salman Bhat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.